[Retracted] Effect of integrin receptor‑targeted liposomal paclitaxel for hepatocellular carcinoma targeting and therapy
Affiliations: Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
- Published online on: March 3, 2021 https://doi.org/10.3892/ol.2021.12611
- Article Number: 350
Copyright : © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
This article is mentioned in:
Oncol Lett 10: [Related article:] 77-84, 2015; DOI: 10.3892/ol.2015.3242
Subsequently to the publication of the above paper, it has been brought to the attention of the Editor that there were a number of striking similarities between the article and another paper published in a different journal by different authors located at different research institutions. First, numerous textual similarities were noted between several paragraphs of the text comparing between this paper and the other paper, which was published in Oncology Reports, also in 2015: Wang R-H, Cao H-M, Tian Z-J, Jin B, Wang Q, Ma H and Wu J: Efficacy of dual-functional liposomes containing paclitaxel for treatment of lung cancer. Oncol Rep 33: 783–791, 2015. Furthermore, Fig. 9 in the above article contained data plots that were also strikingly similar to those included in Fig. 9 in the paper published in Oncology Reports.
After having considered these aspects, the Editor of Oncology Letters has decided that the above paper should be retracted from the publication on the grounds of a lack of certainty regarding the independence and integrity of the study. The authors were contacted in this regard, but did not offer any rebuttal in light of the Editor's decision to retract this paper. Note that the study by Wang et al in Oncology Reports has also been retracted. The Editor regrets any inconvenience that this retraction has caused.